Beta-blockers and heart failure

Indian Heart Journal

Volumn 62, Issue 2, 2010, Pages 101-110

  Cruickshank, John M ^a  

^a Oxonian Cardiovascular consultancy   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ATENOLOL; BETA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; BETA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; BUCINDOLOL; CARVEDILOL; CLENBUTEROL; DIURETIC AGENT; ENALAPRIL; METOPROLOL; NEBIVOLOL; PLACEBO; PROPRANOLOL; XAMOTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ARTICLE; BRONCHOSPASM; CARDIAC PATIENT; CARDIOVASCULAR MORTALITY; DIASTOLIC HEART FAILURE; DIZZINESS; DRUG WITHDRAWAL; ERECTILE DYSFUNCTION; HEART FAILURE; HUMAN; HYPERTENSION; INSOMNIA; INSULIN HYPOGLYCEMIA; LOW DRUG DOSE; METABOLIC DISORDER; NIGHTMARE; ORTHOSTATIC HYPOTENSION; SEXUAL DYSFUNCTION; SUDDEN DEATH; SYSTOLIC HEART FAILURE; SYSTOLIC HYPERTENSION; ADULT; CLINICAL TRIAL (TOPIC); COMPARATIVE STUDY; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; MIDDLE AGED; MORTALITY; OBESITY; PATHOPHYSIOLOGY; PRIMARY PREVENTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW;

ADRENERGIC BETA-1 RECEPTOR ANTAGONISTS; ADULT; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CLINICAL TRIALS AS TOPIC; HEART FAILURE; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; MIDDLE AGED; MYOCARDIAL INFARCTION; OBESITY; PRIMARY PREVENTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 79952279413     PISSN: 00194832     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (120)

1. McMurray JJ, Pfeffer MA. Heart failure. Lancet 2005;365:1877-89
2. Wood DA Preventing clinical heart failure: the rationale and scientific evidence. Heart 2002;88(2):15-22.
3. Lloyd-Jones DM, Larson MG, Leep EP et al. Lifetime risk of developing congestive heart failure. The Framingham Heart Study. Circulation 2002;106:3068-72.
4. Levy D, Kenchaiah S, Larson MG et al. Long-termtrends in the incidence of and sunival with heart failure. N Engl J Med 2002;347:1397-402.
5. Jhund PS, Maclntyre K, Simpson CR et al. Long-term trends in first hospitalisation for heartfailure and subsequent survival between 1996 and 2003. Circulation 2009;119:515-23.
6. st century? Heart 2003;89:49-53.
7. Gheorghiade M, Sopko G, De Luca L et al. Navigating the crossroads of coronary artery disease and heart failure. Circulation 2006;114:1202-13.
8. Jessup M, Brozena S. Heartfailure. N Engl J Med 2003;348:2007-18
9. Kenchaiah S, Evans JQ Levy D et al. Obesity and the risk of heart failure. N Engl J Med 2002:347:305-13.
10. Stork S, Bohin V, Horf R et al. Stimulating autoantibodies directed against the cardiac beta-1 adrenergic receptor predict increased mortality in idiopathic cardiomyopathy. Am Heart J 2006;152:697-704.
11. Jane-wit D, Altuntas CZ, Johson JM et al. Beta-1 adrenergic receptor autoantibodies mediate dilated cardiomyopathy by agonistically inducing cardiomyocyte apoptosis. Circulation 2007;116:399-410.
12. Jalms R, Boivin V, Siegmund C, tnselmann G, Lohse MJ, Boege F. Autoantibodies activating hitman bcta-1 adrenergic receptors are associated with reduced cardial function in chronic heart failure. Circulation 1999;99:649-54.
13. Blackledge HM, Tomlinson J, Squire IB. Prognosisfor patients newly admitted to hospital with heart failure: survival trends in 12,220 index admissions in Leicestershire 1993-2001. Heart 2003:89:615-620.
14. Lee DS, Austin PC, Rouleau JL, Liu PP, Naimark D, Tu JV. Predicting mortality among patients hospitalised for heart failure. JAMA 2003;290:2581-87.
15. Blackledge HM, Newton J, Squire IB. Prognosis for South Asian and white patients newly admitted to hospital with heart failure in the United Kingdom historical cohort study. BMJ 2003;327:526-30.
16. Wong TJ, Evans JC, Benjamin EJ, Levy D, LeRoy EC, Vasan RS. Natural history of asymptomatic left ventricular systolic dysfunction in the community. Circulation 2003;108:977-82.
17. Tribouilloy C, Rusinaru D, Mahjoub H et al. Prognosis of heart failure with preserved ejection fraction: a 5 year prospective population-based study. Eur Heart J 2008;29:339-47.
18. Vasan RS. Diastolic heart failure BMJ 2003;327:1181-2.
19. Aurigetnma GP, Gaasch WH. Diastolic heart failure. N Engl J med 2004;351:1097-105.
20. Westermann D, Kasner M, Steendijk P et al. Role of left ventricular stiffness in heart failure with normal ejection fraction. Circulation 2008;117:2051-60.
21. Kitynan DW, Little WC, Brubaker PH. Pathophysiological cliaracterization of isolated diastolic heart failure in comparison to systolic heart failure. JAMA 2002;288:2144-50.
22. Haber HL, Simek CL, Gimple LW. Why do patients with congestive heart failure tolerate the initiation of beta-blocker tlierapy? Ciradation 1993;88:1610-19.
23. Greenblatt DJ, Koch-Weser J. Adverse reactions of propranolol in hospitalised medical patients: a report from the Boston Collaborative Drug Surveillance Program. Am Heart J 1973;86:478-84.
24. Ertl G, Neubauer S, Gaudron P et al. Beta-blockers in cardiac failure. Eur Heart J 1994;15(suppl c):16-24.
25. Chadda K, Goldstein S, Byington R, Curb JD. Effect of propranolol after acute myocardial infarction in patients with congestive heart failure. Circulation 1986;73:503-10.
26. Norweigian Multicentre Study Group. Timolol-induccd reduction in mortality and reinfarction in patients surviving acute myocardid in farction. N Engl J Med 1081;304:801-07.
27. Waagstcin F, Bristow MR, Swedberg K et al. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Metolpolol in Dilated Cardiomyopathy (MDC) Trial Study Group. Lancet 1993;342:1441-6.
28. CIB1S-I1 investigators and committee. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999;353:9-13.
29. The MERIT-HR Investigators. Effect of metoprolol CR/XL in chronic heart failure. Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HR). Lancet 1999;35:2001-
30. Packer M, Coats AJ, Fowler MB et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001;344:1651-8.
31. Xamoterol in Severe Heart Failure Study Group. Xamoterol in severe heart failure. Lancet 1990;336:1-6.
32. The Beta-blocker Evaluation of Survival Trial Investigators. A trial of the beta-blocker bucindolol in patients with advanced chronic hcart failure. N Engl J Med 2001;344:1659-67.
33. Flather MD, Slubata MC, Coats AJ et al. Randomised trial to determine the effect of nebivolol on mortality and cardiovascular hospital admissions in elderly patients with heart failure (SENIORS). Eur Heart J 2005;26:215-25.
34. Deedwania PC Gottlieb S, Ghali JK Waagstein F, Wikstrand JC; for the MERIT-HF Study Group. Efficacy, safety and tolerability of beta-adrenergic blockade with metoptolol CR/XL in elderly patients with heart failure. Eur Herat J 2001;25:1300-09.
35. Goldstien S, Deawania P, Gottlieb S, Wikstrand J, for the MERIT-HF Study Group. Metoprolol CR/XL in black patients with heart failure (from the metoprolol CR/XL randomised Intervention Trial in Chronic Heart Failure). Am J Cardio 2003;92:478-80.
36. Fauchier L, Grimard C, Pierre B et al. Comparison of beta-blocker and digoxin alone and in combinationfor management of patients with atrial fibrillation and heart failure. Am J Cardiol 2009;103:248-54.
37. nd edit. Edinburgh Churchill Livingsone, 1994 p 1106-9.
38. Andreka P, Aiyar N, Olson LC et al. Bucindolol displays intrinsic sympathomemetic in Congesth-e Heart Failure (MERIT-HF). Lancet 1999;353:2001-7.
39. Andreka P, Aiyar N, Olson LC et al. Bucindolol displays intrinsic sympathiomemetic activity in human muocardium. Circulation 2002;105:2429-34.
40. Maack C, Bohm M, Vlaskin L et al. Partial agonist activity of bucmdolol is dependent on the activation stale of the human beta-1 adrenergic receptor. Circulation 2003; 108:348-53.
41. Brostow MR, Krause-Steinrauf H, Nuzzo R et al. Effect of baseline or changes in adrenergic activity on clinical outcomes on the Beta-blocker Evaluation of Survival Trial. Circulation 2004;110:1437-42.
42. Floras JS. The "unsympathetic" nervous system of heart failure. Circulation 2002;105:1753-5.
43. Dessy C, Moniotte S, Ghisdal P, Havaux X, Noirhomme P, Balligand JL Endothelial beta-3 adreoceptors mediate vaso relaxation of human coronary mkroarteries through nitric oxide and endothelium-dependent hyperpolarisation. Circulation 2004;110:948-54.
44. Maffei A, Di Pardo A, Carangi R et al. Nebivolol induces nitric oxide release in the heart through inducible nitric oxide synthase activation. Hypertension 2007;50:652-6.
45. Moniotte S, Kobzk L, Feron O, Trochu J-P, Gauthier C, Balligrad J-L. Upregulation of beta-3 adrenoceptors and altered contractile response to inotropic amines in human failing myocardium. Circulation 2001;103:1649-55.
46. Gauthier C, Leblais V, Kobzik L et al. The negative inotropic effect of beta-3 adrenoceptor stimulation is mediated by actvalion of a nitric oxide syntliase pathway in human ventricle. J Clin Invest 1998;102:1377-84.
47. Schulman SP, Becker LC, Kass DA L-Arginine therapy in acute myocardial infarction. JAMA 2006;295:58-64.
48. Packer M, Bristow MR, Cohn JM et al. The effect ofcarvedilol on morbidity and mortality in patients with chronic heart failure. New Engl J Med 1996;334:1349-55.
49. The CAPRICORN Investigators. Effect of carvediolol on outcome after myocardial infarction in patients with left-ventricular dysfunction the CAPRICORN randomised trial. Lancet 2001;357:1385-90.
50. Shaddy RE, Boucek MM, Hsu DT et al. Carvedilol for children and adolescents with heart failure. JAMA 2007;298:1171-79.
51. Poole-wibon PA, Swedberg K, Cleland JG et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the carvedilol ormetoprolol European Trial (COMET): randomised controlledtrial. Lancet 2003;362:7-13.
52. Dargie HJ. Beta-blockers in heart failure Lancet 2003;362:2-3.
53. Correspondence. COMET: a proposed mechanism of action to explain the results and concerns about dose. Lancet 2003;362:1076-8.
54. Sanderson JE, Yip GW. Heart failure with a normal ejectionfraction. BMJ 2009;338:b52 doi:10.1136/bmj.b52.
55. Willenheimer R, van Velduisen JJ, Silke B et al. Effect on survival and hospitalisation of initiating treatment of chronic heart failure with bisoprolol followed by enalapril as compared with the opposite sequence. Results of the Randomised Cardiac Insufficiency Study (CIBIS III). Circulation 2005;112:2426-35.
56. CIBIS III triad. Bisoprolol treatment for congestive heart failure leads to 46% redaction in sudden death after one year. Cardiovasc. JS Afr 2006; 17:278.
57. Cruickshank JM. Are we misunderstanding beta-blockers. Int J Cardio 2007;120:10-27.
58. Bellenger NG, Rajappan K Rahman SL et al. Effect of carvedilol on left-ventricular remodelling in chronic stable heart failure: a cardiovascular magnetic resonace study. Heart 2004:90:7604.
59. Communal C, Singh K Sawyer DB, Colucci WS. Opposing effects of beta-1 and beta-2 adrenergic receptors on cardiac myocyte apoptosis. Circulation 1999;100:22102.
60. Cruickshank JM, Degaute JP, Kuume T et al. Reduction in stress/catecholamine-induced cardiac necrosis by beta-1 selective blockade. Lancet 1987;ii:585-9.
61. Reiken S, Gabujakova M, Gaburjakova J et al. Beta-adrenergic receptor blockers restore cardiac calcium release channel (ryanodine receptor) structure and function in heart failure. Circulation 2001;104:2843-8.
62. Gong H, Hong S, Koch WJ et al. Specific beta-2 blocker ICI 118,551 actively decreases contraction through a Gi-coupledfonn of the beta-2 AR in myocytes from failing human heart Gradation 2002;105:2497-503.
63. Anyanwu A Treasure T. Prognosis after lieart transplantation. Transplants alone cannot be the solution for end stage heart failure. BMJ 2003;326:509=10.
64. Birks EJ, Tansley PD, Hardy J et al. Left ventricular assist device and drug tlierapy for the reversal of heart failure. N Engl J Med 2006;355:1873-84.
65. Henandez AF, Hammill BG, O'Connor CM, Sciiulman KA Curtis LH, Fonarow GC Clinical effectiveness ofbeta-blockers in heart failure: findings from the OPTIMIZE-HF Registry. J Am Coll Cardiol 2009;53:184-92.
66. Voors AA de Jong M. Treating diastolic heart failure. Heart 2008;94:971-2.
67. Gheorghiade M, Colucci WS, Swedberg K. Beta-blockers in chronic heart failure. Circulation 2003;107:15705.
68. Shelton RJ, Rigby AS, Cleland JG, Clark AL Effect of a community heart failure clinic on uptake ofbeta-blockers by patients with obstructive airways disease and heart failure. Heart 2006;92:331-6.
69. van de Ven LL, van Leeuwen JT, Smit AJ. The influence of chronic treatment with beta-blockade and angiotensin converting enzyme inhibition on the peripheral blood flow in hypertensive patients with and without concomitant intermittent claudication. J Vasc Dis 1994;23:357-62.
70. Roberts DH, Tsao Y, McLoughlin GA Breckenridge A Placebo-controlled comparison of captopril atenolol, labetalol, and pindolol in hypertension complicated by intermittent claudication. Lancet 1987;2:650-3.
71. UK Prospective Diabet4s Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998;317:703-13.
72. UK prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 1998, 317:713-20.
73. COMMIT(Clopidogrel and Metoprolol in Myocardial Infarction Trial). Early intravenous and oral metoprolol in 45,852 patients with acute myocardial infarction; randomised placebo-controlled trial. Lancet 2005;366:1622-32.
74. Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta-blockade during and after myocardial infarction: an over view off the randomise trials. Prog Cardiovasc Dis 1985;XXVII (5):335-71.
75. Rochon PA, Tu JV, Anderson GM et al. Rate of heart failure and 1-year survival for older people receiving low-dose beta-blocker therapy after myocardial infarction. Lancet 2000:356:63944.
76. Kostis JB, Davis BR, Cutler J et al. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. SHEP Cooperative Research Group. JAMA 1997;278:212-6.
77. The ALLHAT Officers and coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomised to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. JAMA 2002;288:2981-97.
78. Davis BR, Kostis JM, Simpson LM et al: ALLHAT Collaborative Research Group. Heart Failure with preserved and reduced left-vantricular ejection fraction in the antihypertertsive and lipid-lowering treatment to prevent heart attack trial. Circulation 2008:118:2259-67.
79. Anderson K, Wilson PW, Odell PM, Kannel WB. An updated coronary risk profile - a statement for Health Professions. Circulation 1991;83:356-62.
80. Muiesan MI, Salvetti M, Paini A et al. Inappropriate left-vertricular mass changes during treatrnent adversely affects cardiovascular prognosis in hypertensive patients. Hypertension 2007;49:1077-83.
81. Sugishita Y. Aida K, Ohtsukas, Yamaguchi I. Ventricular wall stress revisited A keystone of cardiology. Jpn Heart J 1994;35:577-87.
82. Bums J, Skananthan MV, Ball SG, Mackintosh AF, Marg DA Greenwood JP. Relationship between central sympathetic drive and MR1 imaging-determined left-ventricular mass in essential hypertension. Circulation 2007;115:1999-2005.
83. Kelm M, Schafer S, Mingers S et al. Left-ventricular mass is linked to cardiac noradrenaline in normotenshe and hypertensive patients. J Hypertens 1996;14:1365-7.
84. Schlaich MP, Kaye DM, Lambert E, Somerville M, Socratous F, Esler MD. Relation between cardiac sympathetic activity and hypertensive left-ventricular hypertrophy. Circulation 2003;108:560-5.
85. Seeland V, Selejan S, Engelhardt S, Muller P, Lohse MJ, Bohn M. Interstitial remodelling in beta-1 adrenergic receptor trans-genic mice. Basic Res Cardio 2007;102:183-93.
86. AsaiK Yang EP, Geeng YJ et al. Beta adrenergic blockade arrests myocardial damage and preserves cardiac function in the trans-genic G (salpha) mouse. J Clin Invest 1999;104:551-8.
87. Tallaj J, Wei C-C, Hankes GH et al. Beta-1 adrenergic receptor blockade attenuates angiotensin U-mediated catecholamine reddlease into the cardiac interstitium in mitral regurgitation. Circulation 2003;1089:225-30.
88. Franklin SS, Pio JR. Wong ND, Larson MG, Leip EP, Vasan RS. Predictors of new-onset diastolic and systolic hypertension. The Framingham heart Study. Circulation 2005;111:1121-7.
89. Agabiti-Rosei E, Marcia G, O'Rourke MF et al. Central blood pressure measurements and antihypertensive therapy. A consensus document Hypertens 2007;50:154-60.
90. Cruickshank JM, Lewis J, Moore V, Dodd C Reversibility of left-ventricular hypertrophy by differing types of antihypertensive therapy. J Hum Hypertens 1992;6:85-90.
91. Schulman SP, Weiss JL, Becker LC et al. Effect of antihypertensive therapy on left-ventricular mass in elderly patients. N Engl J Med 1990;322:1350-6.
92. Offili EO, Cohen JP, Vrain JA et al. Effect of treatment of isolated systolic hypertension on left-ventricular mass. JAMA 1998;279:778-80.
93. Cruickshank JM, Higgins TJ, Pennart K, Thorpe JM, Zacharias FM, Zacharias FJ. The efficacy and tolerability of antihypertensive treatment based on atenolol in me prevention of stroke and the regression of left-veraricular hypertrophy. J Hum Hypertens 1987:1:87-93.
94. Otterstad JE, Froeland G, Soeyland AK, Kautsen KM, Ekeli T. Changes in left-ventriadar dimensions and systolic function in 100 mildly hypertensive men during one year's treatment with atenolol vs hydrochlorthiazide and amiloride. J Intern Med 1992;231:493-501.
95. Franz IW, Behr V, Ketelhut R, Tonnesmann V. Decreasing the antihypertensive dosage during long-term treatment and complete regression of left-ventricular hypertrophy. Dtsch Med Wochenschr 1996;121:472-7.
96. de Teresa E, Gonzalez M, Camacho-Vasquez C, Tabuenca MJ. Effects of bisoprolol on left-ventricular hypertrophy in essentialhy pertensin. Cardhasc Drugs Ther 1994;8:837-43.
97. Matuszewska G, Marek B, Kajdanink D, Przyeware-Chowaniec B, Jarzab J, Jarzab B. The importance of bisoprolol in preverition of left-ventlricula rhypertrophy in long-term L-thytoxin suppressive therapy. Endokrynol Pol 2007;58:384-96.
98. Motz W, Vogt M, Scheler S, Schwartzkopff B, Strauer BE. Improvement in coronary reserve following regression of hypertrophy resulting from blood pressure lowering with a beta-blocker. Dtsch Med Wochen. 1993,118:53540.
99. Goss P, Routaut R, Herreo G, Dallocldo M. Beta-blockers vs ACE-inhibition; effects on left-ventricular hypertrophy. J Cardiovasc Pharmacol 1990;16(S): S145-50.
100. nd edition. Edinburgh, Churchill Livingsone;1994:907-1053.
101. UK Prospective Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS38 BMJ 1998;317:703-13.
102. Dorrow P, Bethge M, Tonnesmann V. Effects of single doses of bisoprolol and atenolol on airways function in non-asthmatic chronic obstructive lung disease and angina pectoris. Eur J. Clin Pharmacol 1983;31:143-7.
103. Clausen T, Flatman JA. Beta-2adrenoceptors mediate the stimulating effect of adrenaline on active electrogenic Na-Klransport in rat soleus muscle. Br J Pharmacol 1980;68:749-55.
104. Frisk-Holmberg M, Jorfeldt L, Juhlin-Dannfelt A Metabolic effets in muscle during antihypertensive etherapy with beta-1 and beta-1/-2adrenoceptor blockers. Clin Pharmacol Ther 1981;30:611-18
105. Medical Research Council Working Party. MRC trial of treatment of mild hypertension: principal results. BMJ 1985;291:97-104.
106. IPPPSH Collaborative Group. Cardiovascular risk and risk factors in a randomised trial of treatment based on the beta-blocker oxprenolol J Hypertens 1985;3:379-92.
107. Wikstrand J, Warnold T, Tuomilehto J et al. Melopolol versus diuretic in hypertension. Morbidity results from MAPHY study. Hypertension 1991;17:579-88.
108. Medical Research Council Working Party. MRC trial of treatment of hypertension in older adults: principal results. BMJ 1992;304:405-12.
109. Cryer PE, Haymond MW, Saliago JV, Shar SP. Norepinephrine and epinephrine release and adrenergic mediation of smoking associated haemodynamic and metabolic events. N Engl J Med 1976;295:573-7.
110. Tamow J, Muller RK Cardiovascular effects of low-dose epinephrine infusions in relation to the extent of pre-operative beta-adrenoceptor blockade. Anaesthesiology 1991:74:103543.
111. Deacon SP, Barnett D. Comparison of atenolol and propranolol during insulin-induced hypoglycaemia. BMJ 1976;2:272-3.
112. Lloyd-Mostyn RH, Oram S. Modification by propranolol of cardiovascular effects of induced hypoglycaemia. Lancet 1975;1:1213-5.
113. McMurty RJ. Propranolol hypoglycaemia and hypotensive crises. Ann Intern Med 1974;80:669-70.
114. Krum H, Conway EL, Broadbear JH, Howes LG, Louis WJ. Postural hypotension in elderly patients given carvediloL BMJ 1994;309:775-6.
115. Silvestri A, Galetta P, Cerquetari E et al. Report of erectile dysfunction ofter therapy with beta-blockers is related to patient knowledge of side-effects and is reversed by placebo. Eur Heart J 2003;24:1928-32.
116. Fogari R, Zoppi A Poletti L, Marasi G, Mugellini A Corradi L. Sexual activity hypertensive men treated with valsartan or carvedilol: a cross-over study. Am J Hypertens 2001;14:27-31.
117. Broekman CP, Haensel SM, van den Ven LL, Slob AK. Bisoprolol and hypertension: effects on sexual functioning in men. J Sex and Marital Therapy. 1992;18:325-31.
118. Neil-Dwyer G, Bartlett J, McAinsh JH, Cruickshank JM. Beta-adrenergic blockers and the blood-brain barrier. Br J Clin Pharmac. 1981;11:549-53.
119. Kostis JB, Rosen RC Central nervous system effects of beta-adrenergic blocking drugs; the role of ancillary properties. Circulation 1987;75:204-12.
120. Cruickshank JM, Prichard BN. Beta-blockers in clinical practice. Second edition. Edinburgh, Churchill Livingstone; 1994:940.